<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04771884</url>
  </required_header>
  <id_info>
    <org_study_id>2021-ARC-002</org_study_id>
    <nct_id>NCT04771884</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance</brief_title>
  <official_title>Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital of Chongqing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator's purpose is to study the population pharmacokinetics of commonly used&#xD;
      antimicrobial agents in children of bacterial meningitis with augmented renal clearance and&#xD;
      assess dosage individualization feasibility.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator's purpose is to study the population pharmacokinetics of meropenem,&#xD;
      vancomycin, ceftazidime, ceftriaxone, ceftizoxime and linezolid in children of bacterial&#xD;
      meningitis with augmented renal clearance and assess dosage individualization feasibility. In&#xD;
      this study, the investigator will detect drug concentration in both plasma and cerebrospinal&#xD;
      fluid to construct population pharmacokinetics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">March 20, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 20, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The peak plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid.</measure>
    <time_frame>at (5-10) minutes after intravenous administration</time_frame>
    <description>To detect the peak plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid after intravenous administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The random plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid.</measure>
    <time_frame>at (0.5-10) hours after intravenous administration</time_frame>
    <description>To detect the random plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid after intravenous administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The trough plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid.</measure>
    <time_frame>at 1-2 hours before the next administration</time_frame>
    <description>To detect the trough plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid after intravenous administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical response</measure>
    <time_frame>Through study completion, an average of 14 days</time_frame>
    <description>Blood routine examination, cerebrospinal fluid routine examination and infection indicators (C-reaction protein, procalcitonin)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Bacterial Meningitis</condition>
  <condition>Augmented Renal Clearance</condition>
  <arm_group>
    <arm_group_label>Treatment(meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid)</arm_group_label>
    <description>The use of antimicrobial agents depends on the clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid</intervention_name>
    <description>The use of antimicrobial agents depends on the clinical practice</description>
    <arm_group_label>Treatment(meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Children (2 months-18 years) of bacterial meningitis with augmented renal clearance&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children have been diagnosed with bacterial meningitis with augmented renal clearance&#xD;
             (eGFR ≥ 160 mL/(min*1.73m2));&#xD;
&#xD;
          -  Age: 2 months-18 years;&#xD;
&#xD;
          -  Meropenem, vancomycin, ceftazidime, ceftriaxone, ceftizoxime and/ or linezolid used as&#xD;
             part of regular treatment;&#xD;
&#xD;
          -  Meropenem, vancomycin, ceftazidime, ceftriaxone, ceftizoxime and linezolid was&#xD;
             administered intravenously.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who die within the treatment cycle;&#xD;
&#xD;
          -  Severe congenital malformation;&#xD;
&#xD;
          -  Receive other systemic experimental drug therapy;&#xD;
&#xD;
          -  Other factors that the researchers consider unsuitable for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Zhao, Phd</last_name>
    <phone>86053188383308</phone>
    <email>zhao4wei2@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zhao, Phd</last_name>
      <phone>86053188383308</phone>
      <email>zhao4wei2@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 20, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>April 10, 2021</last_update_submitted>
  <last_update_submitted_qc>April 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Wei Zhao</investigator_full_name>
    <investigator_title>Professor; Head of department of clinical pharmacy and pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningitis, Bacterial</mesh_term>
    <mesh_term>Meningitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Ceftriaxone</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Ceftizoxime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

